PDGFRA FIP1L1-PDGFRA

对伴有FIP1L1-PDGFRA融合的嗜酸细胞增多综合征患者的前瞻性试验确定了伊马替尼治疗的显著反应（Gotlib和Cool，白血病2008）。伊马替尼经FDA批准用于治疗患有FIP1L1-PDGFRα融合激酶的成人高嗜酸细胞综合征（HES）和/或慢性嗜酸细胞白血病（CEL）（NDA221588）患者。
Prospective trials of patients with hypereosinophilic syndrome harboring the FIP1L1-PDGFRA fusion identified marked response to imatinib treatment (Gotlib and Cool, Leukemia 2008). Imatinib is FDA approved for the treatment of \u0026quot;adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase\u0026quot; (NDA021588).